Center Laboratories, Inc.

Taipei Exchange 4123.TWO

Center Laboratories, Inc. Return on Equity (ROE) for the year ending December 31, 2023: -5.04%

Center Laboratories, Inc. Return on Equity (ROE) is -5.04% for the year ending December 31, 2023, a -68.51% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Center Laboratories, Inc. Return on Equity (ROE) for the year ending December 31, 2022 was -2.99%, a -131.18% change year over year.
Center Laboratories, Inc. Return on Equity (ROE) for the year ending December 31, 2021 was 9.59%, a -54.46% change year over year.
Center Laboratories, Inc. Return on Equity (ROE) for the year ending December 31, 2020 was 21.06%, a 1,472.50% change year over year.
Center Laboratories, Inc. Return on Equity (ROE) for the year ending December 31, 2019 was -1.53%, a -103.30% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Taipei Exchange: 4123.TWO

Center Laboratories, Inc.

CEO	Ms. Su-Chi Wang
IPO Date	Dec. 31, 2007
Location	Taiwan
Headquarters	No. 3-2, Yuanyuan Street
Employees	182
Sector	Health Care
Industries Pharmaceuticals

Description

Center Laboratories, Inc. engages in the manufacture and trading of various medicines in Taiwan. It engages in the research and development of small molecule drugs; manufacture and sale of pharmaceuticals; development of proteins and antibodies; and pharmaceutical CDMO, medical device, nutritional health and agribiotechnology, stem cell and immune cell therapy, and industry investment fund and venture capital businesses. The company was founded in 1959 and is headquartered in Taipei, Taiwan.

Key trends

Past 5 years